About US
Contact us
-
Merck's Keytruda gives BMS' Opdivo some company with small cell lung cancer nodBristol-Myers Squibb's FDA approval for Opdivo in patients with previously treated small cell lung cancer (SCLC) already has looked shaky since the drugfailed to extend patients' lives in a phase 3 t2019/6/18
-
Bayer: Roche scores first global nod for targeted cancer drug RozlytrekAs cancer treatment continues a march toward increasingly targeted therapies, Roche has secured its first global approval for Rozlytrek, a med designed to fight NTRK fusion-positive tumors and one2019/6/18
-
China's Fosun rallies support for a joint bid for Bayer's animal health unit: reportAs Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest. China’s Fosun International, parent of Fosun Pharma, is2019/6/17
-
Sanofi, Google team up in search of new treatments, marketing solutionsA few months ago, Sanofi tapped its chief medical officer Ameet Nathwani, M.D., to spearhead a digital revolution at the company. And he’s bringing in the big guns to help. The French drugmaker hasjo2019/6/17
-
Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis studyPfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results u2019/6/14
-
Teva recall: Tainted blood pressure drugs continue to show up in U.S. supplyDespite the FDA’s repeated efforts to clear the U.S. drug supply of hypertension drugs tainted with impurities believed to cause cancer, they keep being discovered. The most recent recall is 10 lots2019/6/14
-
Merck helps FDA test blockchain for track and traceThere has been a lot of talk about how blockchain computer technology can better protect the U.S. drug supply chain. Merck & Co. intends to test that theory. The U.S. drugmaker has beeninvited by2019/6/13
-
FDA: Eli Lilly touts Olumiant safety data for unapproved high doseThe path to success for Eli Lilly and Incyte’s rheumatoid arthritis med Olumiant in the U.S. has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Could new long-term sa2019/6/13
-
ADA 2019 goes beyond diabetes as 'holistic' care comes into focusSAN FRANCISCO—If you’d popped into just a few sessions at the American Diabetes Association annual meeting, you easilycould have thought you’d wandered into a cardiovascular meeting, a kidney disease2019/6/12
-
Judge holds up Teva's $85M opioid settlement, sinking shares back to pre-2000 levelsTeva made headlines late last month when it inked an $85 million settlement with Oklahoma prosecutorsover opioid mismarketing allegations—even after CEOKåre Schultz said the company wouldn't strike2019/6/12